Loss of tumor suppressor gene function in human cancer: an overview
LH Wang, CF Wu, N Rajasekaran… - Cellular Physiology and …, 2019 - karger.com
Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two
types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research …
types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research …
Endometrial cancer
P Morice, A Leary, C Creutzberg, N Abu-Rustum… - The Lancet, 2016 - thelancet.com
Endometrial cancer is the most common gynaecological tumour in developed countries, and
its incidence is increasing. The most frequently occurring histological subtype is …
its incidence is increasing. The most frequently occurring histological subtype is …
Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …
Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology
WJ Koh, NR Abu-Rustum, S Bean, K Bradley… - Journal of the National …, 2018 - jnccn.org
Endometrial carcinoma is a malignant epithelial tumor that forms in the inner lining, or
endometrium, of the uterus. Endometrial carcinoma is the most common gynecologic …
endometrium, of the uterus. Endometrial carcinoma is the most common gynecologic …
Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and …
KJ Monahan, N Bradshaw, S Dolwani, B Desouza… - Gut, 2020 - gut.bmj.com
Heritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost
30% of the population in the UK have a family history of CRC. The quantification of an …
30% of the population in the UK have a family history of CRC. The quantification of an …
Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with …
AN Bartley, AM Mills, E Konnick… - … of pathology & …, 2022 - meridian.allenpress.com
Context.—The US Food and Drug Administration (FDA) approved immune checkpoint
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …
[HTML][HTML] The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis
NAJ Ryan, MA Glaire, D Blake, M Cabrera-Dandy… - Genetics in …, 2019 - Elsevier
Purpose Endometrial cancer (EC) is often the sentinel cancer in women with Lynch
syndrome (LS). However, efforts to implement universal LS screening in EC patients have …
syndrome (LS). However, efforts to implement universal LS screening in EC patients have …
[HTML][HTML] Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 …
Background In this study, we assessed the activity of durvalumab, an antibody to
programmed death ligand-1, in two cohorts of women with advanced endometrial cancers …
programmed death ligand-1, in two cohorts of women with advanced endometrial cancers …
Endometrial cancer in Lynch syndrome
S Zhao, L Chen, Y Zang, W Liu, S Liu… - … Journal of Cancer, 2022 - Wiley Online Library
Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline
pathogenic variants (PVs) in mismatch repair (MMR) genes. LS‐associated endometrial …
pathogenic variants (PVs) in mismatch repair (MMR) genes. LS‐associated endometrial …
Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer
Lynch syndrome (LS) is an autosomal dominant inherited disorder caused by germline
mutations in DNA mismatch repair (MMR) genes. Mutation carriers are at substantially …
mutations in DNA mismatch repair (MMR) genes. Mutation carriers are at substantially …